<unk>  was previously associated with high mortality rates. In 2005, the survival rate was below 50% at three years from diagnosis. More recent reports of patients treated with Interferon therapy describe an overall 5-year survival of 68%. Long-term survival is currently even more promising, although this impression is not reflected in the recent literature. More recent studies have reported that patients receiving targeted therapies showed no disease progression. It was concluded that targeted therapies (BRAF and/or MEK inhibitors) were dramatically efficacious.
Erdheim–Chester disease
Winchester syndrome
Copenhagen disease
Juvenile idiopathic arthritis
Calcium pyrophosphate dihydrate crystal deposition disease
Rheumatoid nodulosis
Secondary systemic amyloidosis
Reactive arthritis